Breaking News
US NAVY USELESS: China Activates "Land Route" to Drain Russian Silver
Lego's next-gen bricks make your creations interactive
Perhaps We Should Actually Be Focusing On Fixing America
Not Worth a ContinentalTop Tech News
The First Production All-Solid-State Battery Is Here, And It Promises 5-Minute Charging
See inside the tech-topia cities billionaires are betting big on developing...
Storage doesn't get much cheaper than this
Laser weapons go mobile on US Army small vehicles
EngineAI T800: Born to Disrupt! #EngineAI #robotics #newtechnology #newproduct
This Silicon Anode Breakthrough Could Mark A Turning Point For EV Batteries [Update]
Travel gadget promises to dry and iron your clothes – totally hands-free
Perfect Aircrete, Kitchen Ingredients.
Futuristic pixel-raising display lets you feel what's onscreen
Cutting-Edge Facility Generates Pure Water and Hydrogen Fuel from Seawater for Mere Pennies
DARPA Nucleic Technology Funded to Get Virus Response to 1-60 Days
The P3 teams are developing technologies to deliver antibodies using nucleic acid technology, and achieve sufficient serum concentrations of the antibodies for protection against the pathogen within three days after administration.
DARPA has programs for Pandemic Prevention Platform, Nucleic Acids On-Demand Worldwide (NOW), and PReemptive Expression of Protective Alleles and Response Elements (PREPARE) programs.
Nucleic Acids On-Demand Worldwide (NOW)
The goal of the NOW program is to develop a mobile medical countermeasure (MCM) manufacturing platform for use in stabilization and humanitarian operations to produce, formulate, and package hundreds of doses of nucleic acid therapeutics (DNA and/or RNA) in less than 24 hours. The developed platform should be a resilient, mobile, readily accessible nucleic acid MCM manufacturing capability that enables immediate threat response anywhere the military operates with minimal user intervention.